View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2015	Aug. 07, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Celsion CORP
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		23,027,988
Amendment Flag	false
Entity Central Index Key	0000749647
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 11,950,991	$ 12,686,881
Investment securities – available for sale, at fair value	18,778,343	24,173,406
Accrued interest receivable on investment securities	51,765	210,030
Advances, deposits and other current assets	684,317	435,954
Total current assets	31,465,416	37,506,271
Property and equipment (at cost, less accumulated depreciation of $1,849,517 and $1,633,517, respectively)	1,009,408	1,170,497
Other assets:
Total other assets	27,939,654	28,017,764
Goodwill	1,976,101	1,976,101
Deposits, deferred fees and other assets	152,450	226,810
Total assets	60,414,478	66,694,532
Current liabilities:
Accounts payable – trade	3,202,950	3,480,225
Other accrued liabilities	2,235,966	2,456,365
Notes payable – current portion	3,865,219	3,654,231
Deferred revenue – current portion	500,000	500,000
Total current liabilities	9,804,135	10,090,821
Earn–out milestone liability	13,905,238	13,663,710
Common stock warrant liability	0	275,008
Notes payable – non-current portion	4,286,345	6,053,065
Deferred revenue – non-current portion	3,250,000	3,500,000
Other liabilities - non-current	63,408	286,592
Total liabilities	31,309,126	33,869,196
Stockholders' equity:
Preferred stock, $0.01 par value: 100,000 shares authorized; no shares issued or outstanding at June 30, 2015 and December 31, 2014, respectively	0	0
Common stock, $0.01 par value; 75,000,000 shares authorized; 23,099,103 and 20,097,603 shares issued at June 30, 2015 and December 31, 2014, and 23,006,186 and 19,984,203 shares outstanding at June 30, 2015 and December 31, 2014, respectively	230,991	200,976
Additional paid-in capital	238,644,773	229,778,703
Accumulated other comprehensive loss	(4,315)	(16,032)
Accumulated deficit	(208,074,411)	(195,073,702)
Subtotal	30,797,038	34,889,945
Treasury stock, at cost (92,917 and 113,400 shares at June 30, 2015 and December 31, 2014, respectively)	(1,691,686)	(2,064,609)
Total stockholders' equity	29,105,352	32,825,336
Total liabilities and stockholders' equity	60,414,478	66,694,532
In Process Research and Development [Member]
Other assets:
Finite lived intangible assets, net	25,801,728	25,801,728
Patents [Member]
Other assets:
Finite lived intangible assets, net	$ 9,375	$ 13,125

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accumulated depreciation (in Dollars)	$ 1,849,517	$ 1,633,517
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	100,000	100,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	23,099,103	20,097,603
Common stock, shares outstanding	23,006,186	19,984,203
Treasury stock, shares	92,917	113,400

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Licensing revenue	$ 125,000	$ 125,000	$ 250,000	$ 250,000
Operating expenses:
Research and development	3,567,699	3,165,473	8,074,107	6,058,641
General and administrative	1,801,843	2,305,208	3,833,683	4,739,065
Acquisition costs		1,067,267		1,067,267
Total operating expenses	5,369,542	6,537,948	11,907,790	11,864,973
Loss from operations	(5,244,542)	(6,412,948)	(11,657,790)	(11,614,973)
Other (expense) income:
Loss from change in valuation of common stock warrant liability	(18,018)	(18,613)	(61,246)	(15,587)
Loss from valuation of earn-out milestone liability	(69,392)		(241,528)
Investment income, net	16,865	23,734	33,245	30,753
Interest expense	(360,259)	(263,115)	(752,562)	(493,828)
Other income (expense)	601	(2,488)	68	(2,488)
Total other (expense) income, net	(430,203)	(260,482)	(1,022,023)	(481,150)
Net loss	$ (5,674,745)	$ (6,673,430)	$ (12,679,813)	$ (12,096,123)
Net loss per common share
Basic and diluted (in Dollars per share)	$ (0.27)	$ (0.38)	$ (0.62)	$ (0.71)
Weighted average shares outstanding
Basic and diluted (in Shares)	20,969,821	17,526,531	20,477,344	16,931,914

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Changes in:
Realized loss on investment securities recognized in investment income, net	$ 339	$ 3,081	$ 210	$ 23,691
Unrealized gain on investment securities	3,300	12,987	11,507	8,646
Other comprehensive gain	3,639	16,068	11,717	32,337
Net loss	(5,674,745)	(6,673,430)	(12,679,813)	(12,096,123)
Comprehensive loss	$ (5,671,106)	$ (6,657,362)	$ (12,668,096)	$ (12,063,786)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net loss	$ (12,679,813)	$ (12,096,123)
Non-cash items included in net loss:
Depreciation and amortization	219,750	174,750
Change in fair value of common stock warrant liability	61,246	15,587
Change in fair value of earn-out milestone liability	241,528
Deferred revenue	(250,000)	(250,000)
Stock-based compensation	1,310,081	1,721,476
Shares issued out of treasury	52,027	30,801
Amortization of deferred finance charges and debt discount associated with notes payable	245,230	176,229
Change in deferred rent liability	(13,999)	(11,280)
Loss realized on sale of investment securities	210	23,691
Net changes in:
Accrued interest on short term investments	158,265	(79,099)
Prepaid expenses, deposits and other assets	(248,363)	189,042
Accounts payable - trade	(486,460)	1,932,916
Accrued liabilities	(220,399)	(834,533)
Net cash used in operating activities	(11,610,697)	(9,006,543)
Cash flows from investing activities:
Purchases of investment securities	(15,487,755)	(22,491,879)
Proceeds from sale and maturity of investment securities	20,894,325	19,490,000
Cash used in acquisition of EGEN, Inc. assets, net of cash received		(2,820,849)
Refund on security for letter of credit	50,000	50,000
Purchases of property and equipment	(54,911)	(119,745)
Net cash provided by (used in) investing activities	5,401,659	(5,892,473)
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs	7,249,750	13,788,811
Proceeds from note payable		5,000,000
Principal payments on notes payable	(1,776,602)	(10,891)
Net cash provided by financing activities	5,473,148	18,777,920
(Decrease) increase in cash and cash equivalents	(735,890)	3,878,904
Cash and cash equivalents at beginning of period	12,686,881	5,718,504
Cash and cash equivalents at end of period	11,950,991	9,597,408
Supplemental disclosures of cash flow information:
Fair value of common stock issued in acquisition of EGEN, Inc. assets		10,852,266
Interest paid	$ 507,332	$ 317,600

Note 1 - Business Description

6 Months Ended

Jun. 30, 2015

Disclosure Text Block [Abstract]

Nature of Operations [Text Block]

Note 1. Business Description

Celsion Corporation, a Delaware corporation based in Lawrenceville, New Jersey, and its wholly owned subsidiary, CLSN Laboratories, Inc., also a Delaware corporation, referred to herein as “Celsion”, “we”, or “the Company,” as the context requires, is a fully-integrated oncology drug development company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. Our lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer. Our pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. We have three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas™ and TheraSilence™. We are working to develop and commercialize more efficient, effective and targeted oncology therapies based on our technologies, with the goal to develop novel therapeutics that maximize efficacy while minimizing side effects common to cancer treatments.

Note 2 - Basis of Presentation

6 Months Ended

Jun. 30, 2015

Disclosure Text Block [Abstract]

Basis of Accounting [Text Block]

Note 2. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements, which include the accounts of Celsion Corporation and CLSN Laboratories, Inc., have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. All intercompany balances and transactions have been eliminated. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited condensed consolidated financial statements. Operating results for the three and six month periods ended June 30, 2015 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed on March 12, 2015 with the Securities and Exchange Commission (SEC).

The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates.

Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other than those arising in the ordinary course of business.

Note 3 - New Accounting Pronouncements

6 Months Ended

Jun. 30, 2015

Disclosure Text Block [Abstract]

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

Note 3. New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by Financial Accounting Standards Board (FASB) and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations.

In May 2014, the FASB issued Accounting Standards Update No. 2014-09 Revenue from Contracts with Customers (Topic 606). This guidance is intended to improve and converge with international standards regarding the financial reporting requirements for revenue from contracts with customers. It will be effective for our first quarter of 2018 and early adoption is not permitted. We are currently evaluating the impact of adoption of this new accounting pronouncement on our financial statements.

In April 2015, the FASB issued Accounting Standards Update No. 2015-03 Interest – Imputation of Interest (Subtopic 835-30). This guidance is to simplify the presentation of debt issuance costs by recognizing a debt liability in the balance sheet as a direct deduction from that debt liability consistent with the presentation of a debt discount. It will be effective for our first quarter of 2016 and early adoption is permitted. We are currently evaluating the impact of adoption of this new accounting pronouncement on our financial statements.

Note 4 - Net Loss per Common Share

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

Note 4. Net Loss per Common Share

Basic earnings per share is calculated based upon the net income (loss) available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of preferred stock, options and warrants and their equivalents are computed using the treasury stock method.

For the three and six month periods ended June 30, 2015 and 2014, diluted loss attributable to common shareholders per common share was the same as basic loss attributable to common shareholders per common share as all options and warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings attributable to common shareholders per common share as their effect would have been anti-dilutive. The total number of shares of common stock issuable upon exercise of warrants and equity awards were 8,188,708 for the three and six month periods ended June 30, 2015 and were 6,948,415 for the three and six month periods ended June 30, 2014.

Note 5 - Investment Securities - Available for Sale

6 Months Ended

Jun. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Note 5. Investment Securities - Available For Sale

Investment securities available for sale of $18,778,343 and $24,173,406 as of June 30, 2015 and December 31, 2014, respectively, consist of commercial paper and corporate debt securities. They are valued at fair value, with unrealized gains and losses reported as a separate component of Stockholders’ Equity in Accumulated Other Comprehensive Loss.

Investment securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near-term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.

A summary of the cost, fair value and maturities of the Company’s short-term investments is as follows:

	June 30, 2015				December 31, 2014
	Cost		Fair Value		Cost		Fair Value
Short-term investments
Certificate of deposit	$	4,760,000	$	4,760,488	$	5,000,000	$	4,996,568
Bonds- corporate issuances		14,020,888		14,017,855		19,189,438		19,176,838
Total short-term investments	$	18,780,888	$	18,778,343	$	24,189,438	$	24,173,406

	June 30, 2015				December 31, 2014
	Cost		Fair Value		Cost		Fair Value
Short-term investment maturities
Within 3 months	$	7,601,405	$	7,601,830	$	16,881,490	$	16,872,158
Between 3-12 months		11,179,483		11,176,513		7,307,948		7,301,248
Total	$	18,780,888	$	18,778,343	$	24,189,438	$	24,173,406

The following table shows the Company’s investment securities with unrealized holding gains and losses and their fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at June 30, 2015 and December 31, 2014. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other than temporary.

	June 30, 2015					December 31, 2014
Description of Securities	Fair Value		Unrealized Holding Gains (Losses)			Fair Value		Unrealized Holding Gains (Losses)

Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains	$	6,080,493	$	2,329		–		–
Short-term investments with unrealized losses		12,697,850		(4,874	)		24,173,406		(16,032	)
Total	$	18,778,343	$	(2,545	)	$	24,173,406	$	(16,032	)

Investment income, which includes net realized losses on sales of available for sale securities and investment income interest and dividends, is summarized as follows:

	Three Months Ended June 30,
Description of Securities	2015			2014

Interest and dividends accrued and paid	$	38,772		$	277,761
Accretion of investment premium		(21,569	)		(250,946	)
Realized losses		(339	)		(3,081	)
Investment income, net	$	16,865		$	23,734

	Six Months Ended June 30,
Description of Securities	2015			2014

Interest and dividends accrued and paid	$	131,974		$	580,975
Accretion of investment premium		(98,519	)		(526,531	)
Realized losses		(210	)		(23,691	)
Investment income, net	$	33,245		$	30,753

The following table presents the change, by component, in accumulated other comprehensive loss for the first six months of 2015.

	Accumulated Other Comprehensive Loss
Balance at January 1, 2015	$	(16,032	)

Unrealized gains on investment securities		11,507
Realized loss reclassified from other accumulated comprehensive loss		210
Net other comprehensive loss, net		11,717

Balance at June 30, 2015	$	(4,315	)

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Note 6 - Fair Value of Measurements

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

Note 6. Fair Value of Measurements

FASB Accounting Standards Codification (ASC) Section 820 (formerly SFAS No. 157) “Fair Value Measurements and Disclosures,” establishes a three level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:

Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date;

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and

Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability.

The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level 1 inputs) or matrix pricing, which is a mathematical technique widely used in the industry to value debt securities without relying exclusively on quoted prices for the specific securities but rather by relying on the securities’ relationship to other benchmark quoted securities (Level 2 inputs).

Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheet at their estimated fair values primarily due to their short-term nature. There were no transfers of assets of liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the six months ended June 30, 2015 except for the change in the fair market value of the warrant liability and the change in the earn-out milestone liability were included in earnings.

Assets and liabilities measured at fair value are summarized below:

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets / Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:
Recurring items as of June 30, 2015
Short-term investments available for sale	$	18,778,343	$	18,778,343	─	─

Recurring items as of December 31, 2014
Short-term investments available for sale	$	24,173,406	$	24,173,406	─	─

Non-recurring items as of December 31, 2014
In-process research and development (Note 7)	$	25,801,728	─		─	$	25,801,728

Goodwill (Note 7)	$	1,976,101	─		─	$	1,976,101

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets / Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Liabilities:
Recurring items as of June 30, 2015
Common stock warrant liability (Note 13)	─		─	─	─

Earn-out milestone liability (Note 12)	$	13,905,238	─	─	$	13,905,238

Recurring items as of December 31, 2014
Common stock warrant liability (Note 13)	$	275,008	─	─	$	275,008

Earn-out milestone liability (Note 12)	$	13,663,710	─	─	$	13,663,710

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Acquisition of EGEN, Inc.

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

Note 7. Acquisition of EGEN, Inc.

On June 20, 2014, Celsion completed the acquisition of substantially all of the assets of Egen, Inc., an Alabama Corporation (EGEN) pursuant to an Asset Purchase Agreement (EGEN Purchase Agreement). CLSN Laboratories, Inc., a Delaware corporation and a wholly-owned subsidiary of Celsion (CLSN Laboratories), acquired all of EGEN’s right, title and interest in and to substantially all of the assets of EGEN, including cash and cash equivalents, patents, trademarks and other intellectual property rights, clinical data, certain contracts, licenses and permits, equipment, furniture, office equipment, furnishings, supplies and other tangible personal property. In addition, CLSN Laboratories assumed certain specified liabilities of EGEN, including the liabilities arising out of the acquired contracts and other assets relating to periods after the closing date.

The total aggregate purchase price for the acquisition is up to $44.4 million, which includes potential future payments of up to $30.4 million contingent upon achievement of certain milestones set forth in the EGEN Purchase Agreement (Earn-out Payments). At the closing, Celsion paid approximately $3.0 million in cash after expense adjustment and issued 2,712,188 shares of its common stock to EGEN. The shares of common stock were issued in a private transaction exempt from registration under the Securities Act of 1933, as amended (the Securities Act), pursuant to Section 4(2) thereof. In addition, 670,070 shares of common stock are issuable to EGEN on or after August 2, 2016 pending satisfactory resolution of any post-closing adjustments of expenses and EGEN’s indemnification obligations under the EGEN Purchase Agreement (Holdback Shares). A registration statement (File No. 333-198786) was filed on September 16, 2014 and declared effective on September 30, 2014 for the resale of the shares of common stock issued and issuable to EGEN under the EGEN Purchase Agreement.

The Earn-out Payments of up to $30.4 million will become payable, in cash, shares of Celsion common stock or a combination thereof, at Celsion’s option, as follows:

●

$12.4 million will become payable upon achieving certain specified development milestones relating to an ovarian cancer study of GEN-1 to be conducted by the Company or its subsidiary;

●

$12.0 million will become payable upon achieving certain specified development milestones relating to a GEN-1 glioblastoma multiforme brain cancer study to be conducted by us or our subsidiary; and

●

up to $6.0 million will become payable upon achieving certain specified development milestones relating to the TheraSilence^TM technology acquired from EGEN in the acquisition.

On June 9, 2014, Celsion borrowed an additional $5 million pursuant to a certain Loan and Security Agreement dated as of November 25, 2013, by and between Celsion and Hercules Technology Growth Capital, Inc. (see Note 9). Celsion used the loan proceeds to pay the upfront cash payment at closing and certain transaction costs incurred by Celsion in connection with the acquisition.

The EGEN Purchase Agreement contains customary representations and warranties regarding EGEN and Celsion, covenants regarding the conduct of EGEN’s business prior to the consummation of the acquisition, indemnification provisions, termination and other provisions customary for transactions of this nature.

The acquisition of EGEN was accounted for under the acquisition method of accounting which required the Company to perform an allocation of the purchase price to the assets acquired and liabilities assumed. The fair value of the consideration transferred for the acquisition is approximately $27.6 million determined as follows:

Consideration Paid at Closing
Cash, net of cash acquired	$	2,821,000
Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)		9,438,000

Future Consideration
Holdback Shares (670,070 shares of Celsion common stock which were discounted by 38% to reflect the cost of the restriction)		1,441,000
Earn-out Payments (at fair value*)		13,878,000

Total fair value of consideration	$	27,578,000

* The total aggregate purchase price for the acquisition of substantially all the assets of EGEN included potential future Earn-out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statements. As of June 30, 2015, the Company fair valued these milestones at $13.9 million and recognized a non-cash charge of $241,528 as a result of the change in the fair value of these milestones from December 31, 2014.

Under the acquisition method of accounting, the total purchase price is allocated to EGEN’s net tangible and intangible assets and liabilities based on their estimated fair values as of the acquisition date. There were no subsequent adjustments to provisional amounts in finalizing the purchase price allocation of acquisition of substantially all of the assets of Egen, Inc. on June 20, 2014. The following table summarizes the fair values of these assets acquired and liabilities assumed related to the acquisition.

Property and equipment, net		35,000
In-process research and development		25,802,000
Goodwill		1,976,000
Total assets:		27,813,000
Accounts payable and accrued liabilities		(235,000	)
Net assets acquired	$	27,578,000

The purchase price exceeded the estimated fair value of the net assets acquired by approximately $2.0 million which was recorded as goodwill.

Acquired In-Process Research and Development (IPR&D)

Acquired IPR&D consists of EGEN's drug technology platforms: TheraPlas™ and TheraSilence™. The fair value of the IPR&D drug technology platforms was estimated to be $25.8 million as of the acquisition date using the Multi-Period Excess Earnings Method (MPEEM) which is a form of the income approach. Under the MPEEM, the fair value of an intangible asset is equal to the present value of the asset’s incremental after-tax cash flows (excess earnings) remaining after deducting the market rates of return on the estimated value of contributory assets (contributory charge) over its remaining useful life.

To calculate fair value of the IPR&D programs under the MPEEM, we used projected cash flows discounted at a rate considered appropriate given the significant inherent risks associated with drug development by development-stage companies. Cash flows were calculated based on estimated projections of revenues and expenses related to the IPR&D programs and then reduced by a contributory charge on requisite assets employed. Contributory assets included debt-free working capital, net fixed assets and assembled workforce. Rates of return on the contributory assets were based on rates used for comparable market participants. Cash flows were assumed to extend through a seven-year market exclusivity period. The resultant cash flows were then discounted to present value using a weighted-average cost of equity capital for companies with profiles substantially similar to that of Celsion, which we believe represents the rate that market participants would use to value the assets. The projected cash flows were based on significant assumptions, including the indication in which we will pursue development of IPR&D programs, the time and resources needed to complete the development and regulatory approval of IPR&D programs, estimates of revenue and operating profit related to the program considering its stage of development, the life of the potential commercialized product, market penetration and competition, and risks associated with achieving commercialization, including delay or failure to obtain regulatory approvals to conduct clinical studies, failure of clinical studies, delay or failure to obtain required market clearances, and intellectual property litigation.

As of the closing of the acquisition, the IPR&D is considered indefinite lived intangible assets and will not be amortized. IPR&D will be reviewed for possible impairment on an annual basis by each year end or more frequently if events are indicative of impairment.

Pro Forma Information

The following unaudited pro forma information presents our condensed results of operations as if the acquisition of EGEN had occurred on January 1, 2014:

	Three Months Ended June 30,
	2015			2014
Revenues	$	125,000		$	125,000
Loss from operations		(5,244,542	)		(6,214,162	)
Net loss applicable to common shareholders		(5,674,745	)		(6,575,376	)

	Six Months Ended June 30,
	2015			2014
Revenues	$	250,000		$	250,000
Loss from operations		(11,657,790	)		(12,116,500	)
Net loss applicable to common shareholders		(12,679,813	)		(12,582,418	)

The above unaudited pro forma condensed consolidated financial information is presented for illustrative purposes only. It is not necessarily indicative of what the results of operations actually would have been had the acquisition been completed on the date indicated. In addition, it does not purport to project the future operating results of the combined entity.

Goodwill represents the difference between the total purchase price for the net assets purchased from EGEN and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. We will test our goodwill for impairment annually and between annual tests if we become aware of an event or a change in circumstances that would indicate the carrying amount may be impaired.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Note 8 - Accrued Liabilities

6 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 8. Accrued Liabilities

Other accrued liabilities at June 30, 2015 and December 31, 2014 include the following:

	June 30, 2015		December 31, 2014
Amounts due to Contract Research Organizations and other contractual agreements	$	1,084,432	$	857,730
Accrued payroll and related benefits		612,920		961,440
Accrued professional fees		441,500		502,300
Accrued interest on notes payable		77,094		96,875
Other		20,020		38,020

Total Accrued Liabilities	$	2,235,966	$	2,456,365

Note 9 - Note Payable

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Debt Disclosure [Text Block]

Note 9. Note Payable

Hercules Credit Agreement

In November 2013, the Company entered into a loan agreement with Hercules Technology Growth Capital, Inc. (Hercules) which permits up to $20 million in capital to be distributed in multiple tranches (the Hercules Credit Agreement). The Company drew the first tranche of $5 million upon closing of the Hercules Credit Agreement in November 2013 and used approximately $4 million of the proceeds to repay the outstanding obligations under its loan agreement with Oxford Finance LLC and Horizon Technology Finance Corporation as discussed further below. On June 10, 2014, the Company closed the second $5 million tranche under the Hercules Credit Agreement. The proceeds were used to fund the $3.0 million upfront cash payment associated with Celsion's acquisition of EGEN, as well as the Company’s transaction costs associated with the EGEN acquisition. Upon the closing of this second tranche, the Company has drawn down a total of $10 million under the Hercules Credit Agreement.

The obligations under the Hercules Credit Agreement are in the form of secured indebtedness bearing interest at a calculated prime-based variable rate (11.25% per annum since inception). Payments under the loan agreement are interest only for the first twelve months after loan closing, followed by a 30-month amortization period of principal and interest through the scheduled maturity date.

In connection with the Hercules Credit Agreement, the Company incurred cash expenses of $122,378 which were recorded as deferred financing fees. These deferred financing fees are being amortized as interest expense using the effective interest method over the life of the loan. Also in connection with the Hercules Credit Facility, the Company paid loan origination fees of $230,000 which has been classified as debt discount. This amount is being amortized as interest expense using the effective interest method over the life of the loan.

As a fee in connection with the Hercules Credit Agreement, the Company issued Hercules a warrant for a total of 97,493 shares of the Company’s common stock (the Hercules Warrant) at a per share exercise price of $3.59, exercisable for cash or by net exercise from November 25, 2013. Upon the closing of the second tranche on June 10, 2014, this warrant became exercisable for an additional 97,493 shares of the Company’s common stock. The Hercules Warrant will expire November 25, 2018. Hercules has certain rights to register the common stock underlying the Hercules Warrant pursuant to a Registration Rights Agreement with the Company dated November 25, 2013. The registration rights expire on the date when such stock may be sold under Rule 144 without restriction or upon the first year anniversary of the registration statement for such stock, whichever is earlier. A registration statement (File No. 333-193936) was filed on February 13, 2014, amended on September 16, 2014 and declared effective on September 30, 2014 for the resale of the shares of common stock issuable pursuant to the Hercules Warrant.

The Company valued the Hercules Warrant issued at the inception of the loan using the Black-Scholes option pricing model and recorded $521,763 in 2013 as deferred financing fees. In calculating the value of the warrant, the Company assumed a volatility rate of 102%, risk free interest rate of 1.37%, an expected life of 5 years, a stock price of $3.55 (closing price on date of the Hercules Warrant) and no expected forfeitures nor dividends. In the second quarter of 2014, the Company reassessed the classification of the warrant and concluded the original amount should be reclassified from deferred financing fees and equity as the warrant contains a provision which required the exercise price to be adjusted downward to a lower price at which time the Company would sell and issue shares in a financing for cash during the one-year anniversary of the date of issuance of the warrant. Therefore, other assets and additional paid in capital were both reduced by the $521,763. The Company then valued the warrant for the initial 97,493 shares of the common stock as of the inception of the loan and recorded $260,928 as a debt discount to be amortized as interest expense using the effective interest method over the life of the loan and recognized a warrant liability for this amount. In connection with the closing of the second $5 million tranche on June 9, 2014, the Company then valued the warrant for the additional 97,493 shares of the common stock which became available and exercisable as of the date and recorded $215,333 as a debt discount to be amortized as interest expense using the effective interest method over the life of the loan and recognized a warrant liability for this amount. In calculating the value of the warrant for the additional shares of the common stock on June 10, 2014, the Company assumed a volatility rate of 104%, risk free interest rate of 1.69%, an expected remaining life of 4.5 years, a stock price of $3.07 (closing price June 9, 2014) and no expected forfeitures nor dividends. The warrant liability was fair valued at the end of each quarter and the resulting change in fair value will be recognized in net income.

In the second quarter of 2015, the Company concluded the warrant provision which provided for the exercise price to be adjusted downward as described above had expired. Therefore, the Company valued the warrant at $336,254 immediately prior to this event and recorded non-cash charges to net income of $18,018 and $61,246 in the second quarter and year to date periods of 2015, respectively. The Company also reduced the liability to zero and increased equity by $336,254 at this time.

Also in connection with each of the $5.0 million tranches, the Company will be required to pay an end of term charge equal to 3.5% of each original loan amount at time of maturity. Therefore, these amounts totaling $350,000 are being amortized as interest expense using the effective interest method over the life of the loan.

For the three and six month periods ended June 30, 2015, the Company incurred $242,421 and $507,332 in interest expense and amortized $117,838 and $245,230 as interest expense for deferred fees, debt discount and end of term charges in connection with the Hercules Credit Agreement.

The Hercules Credit Agreement contains customary covenants, including covenants that limit or restrict the Company’s ability to grant liens, incur indebtedness, make certain restricted payments, merge or consolidate and make dispositions of assets. Upon the occurrence of an event of default under the Hercules Credit Agreement, the lenders may cease making loans, terminate the Hercules Credit Agreement, declare all amounts outstanding to be immediately due and payable and foreclose on or liquidate the Company’s assets that comprise the lenders’ collateral. The Hercules Credit Agreement specifies a number of events of default (some of which are subject to applicable grace or cure periods), including, among other things, non-payment defaults, covenant defaults, a material adverse effect on the Company or its assets, cross-defaults to other material indebtedness, bankruptcy and insolvency defaults and material judgment defaults. The Company has maintained compliance with these covenants.

Following is a schedule of future principal payments before debt discount due on the Hercules Credit Agreement:

	For the Year ending June 30,

2016	$	3,865,219
2017		4,358,179

Total	$	8,223,398

Oxford & Horizon Credit Agreement

In June 2012, the Company entered into a Loan and Security Agreement (the Oxford & Horizon Credit Agreement) with Oxford Finance LLC (Oxford) and Horizon Technology Finance Corporation (Horizon). The Oxford & Horizon Credit Agreement provided for a secured term loan of up to $10 million, with 50% of any loans to be funded by Oxford and 50% to be funded by Horizon. The aggregate loan amount could have been advanced in two tranches of $5 million each. The first tranche (the Term A Loan) was made available to the Company on June 27, 2012 and the second tranche was to be made available, if at all, during the period beginning on the date that the Company achieved positive data in its Phase III clinical trial of RFA and ThermoDox® (the HEAT Study) and ending on March 31, 2013. On January 31, 2013, the Company announced it did not meet the primary endpoint of the HEAT Study.

The Term A Loan was originally scheduled to mature on October 15, 2015. As a result of the Hercules Credit Agreement discussed above, the Company terminated the Oxford & Horizon Credit Agreement and repaid the outstanding principal, accrued interest and termination fees totaling approximately $4.1 million.

The proceeds of the Oxford & Horizon Credit Agreement were used to fund the Company’s working capital and general corporate purposes. The obligations under the Oxford & Horizon Credit Agreement were secured by substantially all assets of the Company other than its intellectual property and certain other agreed-upon exclusions.

As a fee in connection with the Oxford & Horizon Credit Agreement, the Company issued warrants to Horizon and Oxford (the Oxford & Horizon Warrants) to purchase the number of shares of the Company’s common stock equal to 3% of each loan amount divided by the exercise price of $13.14 per share, which was calculated as the average NASDAQ closing price of the Company’s common stock for the three days prior to the funding of the loan amount. This resulted in 11,415 warrant shares issued in connection with the Term A Loan. The Oxford & Horizon Warrants issued in connection with the Term A Loan are exercisable for cash or by net exercise and will expire seven years after their issuance, which is June 27, 2019.

Note 10 - Stockholders' Equity

6 Months Ended

Jun. 30, 2015

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Note 10. Stockholders’ Equity

May 2015 Common Stock Offering

On May 27, 2015, the Company entered into a Securities Purchase Agreement with certain investors, pursuant to which the Company sold and issued on June 1, 2015, in a registered direct offering (the May 2015 Offering), an aggregate of 3,000,000 shares of common stock at an offering price of $2.675 per share for gross proceeds of $8.0 million before the deduction of the placement agent fee and offering expenses. The Shares were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-183286), which was initially filed with the SEC on August 13, 2012, as amended on August 20, 2012, and was declared effective by the SEC on September 14, 2012 (the Shelf Registration Statement).

In a concurrent private placement closed on June 1, 2015, the Company issued to the investors in the May 2015 Offering certain warrants (the May 2015 Warrants) at an exercise price of $2.60 per share. The May 2015 Warrants are exercisable to purchase 0.65 share of common stock for each share of common stock purchased in the May 2015 Offering for an aggregate of 1,950,000 shares of common stock. Each May 2015 Warrant will be exercisable on the date of its issuance until the five-year anniversary of the date of issuance. On July 10, 2015, the Company filed a registration statement for the resale of any shares of common stock issuable upon the exercise of the May 2015 Warrants on Form S-3 (File No. 333-205608) which was declared effective by the SEC on July 30, 2015.

Under this purchase agreement, the Company is prohibited, for a period of three months after the closing, from effecting or entering into an agreement to issue common stock or, for a period of five months after the closing, any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, common stock to the extent such issuance or sale involves certain variable conversion, exercise or exchange prices or such agreement provides for sale of securities at a price to be determined in the future.

January 2014 Common Stock Offering

On January 15, 2014, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 3,603,604 shares of its common stock and warrants to purchase up to 1,801,802 shares of common stock, for an aggregate purchase price of approximately $15 million (the January 2014 Offering). The shares of common stock and warrants were sold in units, with each unit consisting of one share of common stock, a Series A warrant to purchase 0.25 share of common stock and a Series B warrant to purchase 0.25 share of common stock. Each unit was sold at a purchase price of $4.1625. Each Series A warrant will be exercisable during one year after its issuance date and until the five-year anniversary of the issuance date. Each Series B warrant was exercisable at any time on or after its issuance date had expired as of January 15, 2015. Each warrant has an exercise price of $4.10 per share.

Controlled Equity Offering

On February 1, 2013, the Company entered into a Controlled Equity Offering^SM Sales Agreement (the ATM Agreement) with Cantor Fitzgerald & Co., as sales agent (Cantor), pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its common stock having an aggregate offering price of up to $25.0 million (the ATM Shares) pursuant to the Shelf Registration Statement. Under the ATM Agreement, Cantor may sell ATM Shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for the our common stock or to or through a market maker. From February 1, 2013 through February 25, 2013, the Company sold and issued an aggregate of 1,195,927 shares of common stock under the ATM Agreement, receiving approximately $6.8 million in net proceeds.

The Company is not obligated to sell any ATM Shares under the ATM Agreement. Subject to the terms and conditions of the ATM Agreement, Cantor will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market, to sell ATM Shares from time to time based upon the Company’s instructions, including any price, time or size limits or other customary parameters or conditions the Company may impose. In addition, pursuant to the terms and conditions of the ATM Agreement and subject to the instructions of the Company, Cantor may sell ATM Shares by any other method permitted by law, including in privately negotiated transactions.

The ATM Agreement will terminate upon the earlier of (i) the sale of ATM Shares under the ATM Agreement having an aggregate offering price of $25 million and (ii) the termination of the ATM Agreement by Cantor or the Company. The ATM Agreement may be terminated by Cantor or the Company at any time upon 10 days' notice to the other party, or by Cantor at any time in certain circumstances, including the occurrence of a material adverse change in the Company. The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of ATM Shares and has agreed to provide Cantor with customary indemnification and contribution rights. The Company also reimbursed Cantor for legal fees and disbursements, of $50,000, in connection with entering into the ATM Agreement. We have sold and issued an aggregate of 1,195,927 shares under the ATM Agreement so far, receiving approximately $6.8 million in net proceeds. In connection with the May 2015 Offering, we have agreed not to sell any additional shares under the ATM Agreement until September 1, 2015.

February 2013 Preferred Stock Offering

On February 22, 2013, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company sold, in a registered offering, an aggregate of 15,000.00422 shares of its Series A 0% convertible preferred stock and the warrants to purchase shares of its common stock, for an aggregate purchase price of approximately $15.0 million (the February 2013 Preferred Stock Offering). The closing of the February 2013 Preferred Stock Offering occurred on February 26, 2013, in which the Company received approximately $15.0 million in gross proceeds. Subject to certain ownership limitations, shares of Series A 0% convertible preferred stock are convertible, at the option of the holder thereof, into an aggregate of up to 2,682,764 shares of common stock, and the warrants are exercisable to purchase an aggregate of up to 1,341,382 shares of common stock. Each warrant has an exercise price of $5.31 per share, equal to the closing bid price of common stock on February 21, 2013. The warrants were immediately exercisable and expire five years after the date of issuance.

During 2013, 2,682,764 shares of common stock in the aggregate were issued upon conversion of all of the 15,000.00422 shares of the Series A 0% convertible preferred stock.

Reverse Stock Split

On October 28, 2013, the Company effected a 4.5-to-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on October 29, 2013. As of October 28, 2013, each nine shares of issued and outstanding common stock and equivalents were combined and converted into two shares of common stock outstanding at the time of the reverse stock split.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Note 11 - Stock Based Compensation

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 11. Stock Based Compensation

Stock Options Plans

The Company has long-term compensation plans that permit the granting of incentive awards in the form of stock options. Generally, the terms of these plans require that the exercise price of the options may not be less than the fair market value of Celsion’s common stock on the date the options are granted. Options granted generally vest over various time frames or upon milestone accomplishments. The Company’s options generally expire ten years from the date of the grant.

In 2007, the Company adopted the Celsion Corporation 2007 Stock Incentive Plan (the 2007 Plan) under which 222,222 shares were authorized for issuance. The purpose of the 2007 Plan is to promote the long-term growth and profitability of the Company by providing incentives to improve stockholder value and enable the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The 2007 Plan permits the granting of equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing. At the Annual Meetings of Stockholders of Celsion held on June 25, 2010, June 7, 2012 and June 20, 2014, the stockholders approved amendments to the Plan. The only material difference between the original Plan and the amended Plan was the number of shares of common stock available for issuance under the amended Plan which was increased by 222,222 to a total of 444,444 shares in 2010, by 500,000 to a total of 944,444 shares in 2012 and by 2,500,000 to a total of 3,444,444 shares in 2014.

Prior to the adoption of the 2007 Plan, the Company adopted two stock plans for directors, officers and employees (one in 2001 and another in 2004) under which 148,148 shares were reserved for future issuance under each of these plans. As these plans have been superseded by the 2007 Plan, any options previously granted which expire, forfeit, or cancel under these plans will be rolled into the 2007 Plan.

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Celsion’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate.

The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:

	Six Months Ended June 30,
	2015			2014
Risk-free interest rate		2.06-2.93	%		2.63 - 2.75	%
Expected volatility		92.9-93.0	%		98.7 - 100.72	%
Expected life (in years)		10.00			10.00
Expected forfeiture rate		5	%		5	%
Expected dividend yield		0.0	%		0.0	%

Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk free interest rate is derived from values assigned to U.S. Treasury bonds as published in the Wall Street Journal in effect at the time of grant. The model incorporates exercise, pre-vesting and post-vesting forfeiture assumptions based on analysis of historical data. The expected life of the fiscal 2015 and 2014 grants was generated using the simplified method.

A summary of the Company’s stock option and restricted stock awards for the six months ended June 30, 2015 is as follows:

	Stock Options					Restricted Stock Awards					Weighted Average
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value		Contractual Terms of Equity Awards (in years)

Equity awards outstanding at December 31, 2014		1,744,755		$	7.20		7,018		$	3.32
Equity awards granted		709,250		$	2.44		36,000		$	3.47
Equity awards exercised	–			–			(1,500	)	$	2.54
Equity awards forfeited, cancelled or expired		(201,490	)	$	10.83	–			–
Equity awards outstanding at June 30, 2015		2,252,515		$	5.86		41,518		$	3.48		7.7

Aggregate intrinsic value of outstanding awards at June 30, 2015	–					$	110,853

Equity awards exercisable at June 30, 2015		1,421,390		$	7.56							6.8

Aggregate intrinsic value of awards exercisable June 30, 2015	–

Total compensation cost related to employee stock options and restricted stock awards amounted to $462,468 and $1,035,196 for the six months ended June 30, 2015 and 2014, respectively. Total compensation cost related to employee stock options and restricted stock awards amounted to $1,310,081 and $1,721,476 for the six months ended June 30, 2015 and 2014, respectively. No compensation cost related to share-based payments arrangements was capitalized as part of the cost of any asset as of June 30, 2015 and 2014.

As of June 30, 2015, there was $1.3 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.3 years. The weighted average grant-date fair value was $2.15 and $3.19 per share for the options granted during the six months ended June 30, 2015 and 2014, respectively. The weighted average grant-date fair value was $3.47 and $3.72 for the restricted stock awards granted during the six months ended June 30, 2015 and 2014, respectively.

Collectively, for all of the Company’s stock option plans as of June 30, 2015, there were a total of 3,672,770 shares reserved with 2,294,033 equity awards granted and 1,378,737 equity awards available for future issuance.

Note 12 - Earn-out Milestone Liability

6 Months Ended

Jun. 30, 2015

Earn Out Milestone Liability Disclosure [Abstract]

Earn Out Milestone Liability Disclosure [Text Block]

Note 12. Earn-out Milestone Liability

The total aggregate purchase price for the EGEN Acquisition included potential future Earn-out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone (10% to 67%) and utilizing a discount rate based on the estimated time to achieve the milestone (1.5 to 7.0 years). The earn-out milestone liability will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statements. At June 30, 2015, the Company fair valued the earn-out milestone liability at $13.9 million and recognized a non-cash charge of $69,392 and $241,528 during the three and six month periods ended June 30, 2015, respectively, as a result of the change in the fair value of earn-out milestone liability from $13.8 million and $13.7 million at March 31, 2015 and December 31, 2014, respectively.

The fair value of the earn-out milestone liability at June 30, 2015 was based on the Company's risk-adjusted assessment of each milestone (10% to 67%) utilizing a discount rate based on the estimated time to achieve the milestone (0.9 to 3.0 years). The fair value of the earn-out milestone liability at December 31, 2014 was based on the Company's risk-adjusted assessment of each milestone (10% to 67%) utilizing a discount rate based on the estimated time to achieve the milestone (1.2 to 6.5 years).

The following is a summary of the changes in the earn-out milestone liability for 2015:

Balance at January 1, 2015	$	13,663,710
Non-cash charge from the adjustment for the change in fair value included in net loss		241,528
Balance at June 30, 2015	$	13,905,238

Note 13 - Warrants

6 Months Ended

Jun. 30, 2015

Warrants [Abstract]

Warrants [Text Block]

Note 13. Warrants

Common Stock Warrants

Following is a summary of all warrant activity for the six months ended June 30, 2015:

Warrants	Number of Warrants Issued			Weighted Average Exercise Price

Warrants outstanding at December 31, 2014		5,069,815		$	8.18

Warrants issued during the six months ended June 30, 2015		1,950,000		$	2.60

Warrants expired during the six months ended June 30, 2015		(1,125,140	)	$	7.98
Warrants outstanding at June 30, 2015		5,894,675		$	6.37

Aggregate intrinsic value of outstanding warrants at June 30, 2015	–

Weighted average remaining contractual terms (in years)		3.3

In September 2009, the Company closed a registered direct offering with a select group of institutional investors that raised gross proceeds of $7.1 million and net proceeds of $6.3 million. In connection with this registered direct offering, the Company issued 448,478 shares of its common stock and warrants to purchase 224,239 shares of common stock. On March 31, 2015, all unexercised warrants associated with this registered direct offering expired. As discussed in Note 10, the Series B warrants to purchase 900,901 shares of common stock issued in connection with the January 2014 Offering expired in January 2015.

Common Stock Warrant Liability

As of December 31, 2014, the Company recorded a common stock warrant liability of $275,008. The fair value of the warrants associated with the September 2009 registered direct offering at December 31, 2014 and the warrants associated with the Hercules loan, as more fully described in Note 9, at December 31, 2014 was calculated using the Black-Scholes option-pricing model with the following assumptions:

	December 31, 2014
Risk-free interest rate		0.04 - 1.66	%
Expected volatility		40.9- 98.35	%
Expected life (in years)		0.25 -3.9
Expected forfeiture rate		0.0	%
Expected dividend yield		0.00	%

Under the terms of the warrants associated with the September 2009 registered direct offering, upon certain transactions, including a merger, tender offer or sale of all or substantially all of the assets of the Company, each warrant holder could have elected to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option valuation model. Accordingly, pursuant to ASC 815.40, Derivative Instruments and Hedging - Contracts in Entity’s Own Equity, the warrants were recorded as a liability and marked to market each period through the Statement of Operations in other income or expense. At the end of each subsequent quarter, the Company revalued the fair value of the warrants and the change in fair value was recorded as a change to the warrant liability and the difference was recorded through the Statement of Operations in other income or expense. The warrants expired in March 2015.

As discussed in Note 9, the Company concluded in the second quarter of 2015 the warrant provision which required the exercise price of the warrant to be adjusted downward to a lower price at which the Company would sell and issue shares in a financing for cash during the one-year anniversary of the warrant had expired. Therefore, the Company valued the warrant at $336,254 immediately prior to this event using a risk-free interest rate of 1.98%, expected volatility of 99.71%, an expected remaining life of 4 years and no forfeiture nor dividends expected. The Company recorded non-cash charges to net income of $18,018 and $61,246 in the second quarter and year to date periods of 2015, respectively, and reduced the liability to zero and increased equity by $336,254 at this time.

The following is a summary of the changes in the common stock warrant liability for the six month period ended June 30, 2015:

Beginning balance as of January 1, 2015	$	275,008
Loss from the adjustment for the change in fair value included in net loss		61,246
Fair value of warrants reclassified as equity (Note 9)		(336,254	)
Ending balance as of June 30, 2015	–

Note 14 - Contingent Liabilities and Commitments

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Note 14. Contingent Liabilities and Commitments

In July 2011, the Company, as a tenant, and a landlord executed a lease (the Lease) for a 10,870 square foot premises located in Lawrenceville, New Jersey. In October 2011, the Company relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The Lease has a term of 66 months and provides for 6 months of free rent; with the first monthly rent payment of approximately $23,000 paid in April 2012. Also, as required by the Lease, the Company provided Brandywine with an irrevocable and unconditional standby letter of credit for $250,000, which the Company secured with an escrow deposit at its banking institution of this same amount. The standby letter of credit will be reduced by $50,000 on each of the 19th, 31st and 43rd months from the initial term, with the remaining $100,000 amount remaining until the term of the Lease has expired. In connection with two $50,000 reductions of the standby letter of credit in April 2013 and 2014, the Company reduced the escrow deposit by $50,000 each time. The Company received the third and final reduction in April 2015.

In connection with the EGEN Asset Purchase Agreement in June 2014, the Company assumed the existing lease with another landlord for an 11,500 square foot premises located in Huntsville Alabama. This lease has a remaining term of 32 months with monthly rent payments of approximately $23,200.

Note 15 - Technology Development and Licensing Agreements

6 Months Ended

Jun. 30, 2015

Licensing Transaction [Abstract]

Licensing Transaction [Text Block]

Note 15. Technology Development and Licensing Agreements

On May 7, 2012 the Company entered into a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) for the production of ThermoDox® in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registration and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Celsion will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registration batches of ThermoDox®. Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration (CHINA FDA). During the first quarter of 2015, Hisun completed the successful manufacture of three registration batches of ThermoDox® and the Company accrued $685,787 for the aggregate development costs and fees associated with these batches in March 2015. This amount was paid in April 2015.

On January 18, 2013, we entered into a technology development contract with Hisun, pursuant to which Hisun paid us a non-refundable research and development fee of $5 million to support our development of ThermoDox® in mainland China, Hong Kong and Macau (the China territory). Following our announcement on January 31, 2013 that the HEAT study failed to meet its primary endpoint, Celsion and Hisun have agreed that the Technology Development Contract entered into on January 18, 2013 will remain in effect while the parties continue to collaborate and are evaluating the next steps in relation to ThermoDox®, which include the sub-group analysis of patients in the Phase III HEAT Study for the hepatocellular carcinoma clinical indication and other activities to further the development of ThermoDox® for the Greater China market. The $5.0 million received as a non-refundable payment from Hisun in the first quarter 2013 has been recorded to deferred revenue and will continue to be amortized over the 10 year term of the agreement, until such time as the parties find a mutually acceptable path forward on the development of ThermoDox® based on findings of the ongoing post-study analysis of the HEAT Study data.

On July 19, 2013, the Company and Hisun entered into a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox® as well as the technology transfer relating to the commercial manufacture of ThermoDox® for the China territory. This expanded collaboration includes development of the next generation liposomal formulation with the goal of creating safer, more efficacious versions of marketed cancer chemotherapeutics.

Among the key provisions of the Celsion-Hisun Memorandum of Understanding are:

●

Hisun will provide the Company with non-dilutive financing and the investment necessary to complete the technology transfer of its proprietary manufacturing process and the production of registration batches for the China territory;

●

Hisun will collaborate with the Company around the clinical and regulatory approval activities for ThermoDox® as well as other liposomal formations with the CHINA FDA; and

●

Hisun will be granted a right of first offer for a commercial license to ThermoDox® for the sale and distribution of ThermoDox® in the China territory.

Development, Product Supply and Commercialization Agreement with Yakult Honsha

In the fourth quarter of 2008, the Company entered into a Development, Product Supply and Commercialization Agreement with Yakult Honsha Co. LTD (Yakult) under which Yakult was granted the exclusive right to commercialize and market ThermoDox® for the Japanese market. We were paid a $2.5 million up-front licensing fee and we have the potential to receive additional payments from Yakult upon receipt of marketing approval by the Japanese Ministry of Health, Labor and Welfare as well as upon the achievement of certain levels of sales and approval for new indications. We will receive double digit escalating royalties on the sale ThermoDox® in Japan, when and if any such sales occur. We also will be the exclusive supplier of ThermoDox® to Yakult.

In January 2011, the Company amended its Development, Product Supply and Commercialization Agreement with Yakult to provide for up to $4.0 million in an accelerated partial payment to the Company of a future drug approval milestone, which included $2.0 million paid to the Company upon the closing of the preferred equity financing the Company conducted in January 2011 and an additional $2.0 million conditioned upon the resumption of enrollment of Japanese patients in the Japan cohort of the HEAT Study. In consideration of these accelerated milestone payments from Yakult, the Company agreed to reduce future drug approval milestone payments by approximately 40%.

License and Distribution Agreement

On January 20, 2015 the Company announced it had signed a license and distribution agreement with myTomorrows to implement an Early Access Program for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin, in all countries of the European Union (EU) territory plus Switzerland for the treatment of patients with recurrent chest wall (RCW) breast cancer.

RCW breast cancer is difficult to treat and has a poor prognosis with a significant impact on a patient's quality of life. Patients with highly resistant tumors found on the chest wall often see their cancer progress despite previous treatment attempts including chemotherapy, radiation therapy and hormone therapy. There are approximately 25,000 to 35,000 incidence of RCW breast cancer in the EU alone and thermal therapy is a well-accepted strategy for treating patients. Recent findings from two Phase I studies and an ongoing open label Phase II study indicate that when combined with thermal therapy, ThermoDox® can demonstrate significant overall response rates and tumor control in post mastectomy, refractory patients.

Early Access Programs (EAP) allow biopharmaceutical companies to provide eligible patients with ethical access to investigational medicines for unmet medical needs within the scope of the existing early access legislation. Access is provided in response to physician requests in a fully compliant manner, where no alternative treatment options are available to these patients. Celsion will provide ThermoDox® to centers of excellence in the EU and Switzerland through its Early Access Program with myTomorrows, at prices that are comparable to chemotherapeutics used to treat this and other aggressive form of cancer.

Note 5 - Investment Securities - Available for Sale (Tables)

6 Months Ended

Jun. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Available-for-sale Securities [Table Text Block]

	June 30, 2015				December 31, 2014
	Cost		Fair Value		Cost		Fair Value
Short-term investments
Certificate of deposit	$	4,760,000	$	4,760,488	$	5,000,000	$	4,996,568
Bonds- corporate issuances		14,020,888		14,017,855		19,189,438		19,176,838
Total short-term investments	$	18,780,888	$	18,778,343	$	24,189,438	$	24,173,406

	June 30, 2015				December 31, 2014
	Cost		Fair Value		Cost		Fair Value
Short-term investment maturities
Within 3 months	$	7,601,405	$	7,601,830	$	16,881,490	$	16,872,158
Between 3-12 months		11,179,483		11,176,513		7,307,948		7,301,248
Total	$	18,780,888	$	18,778,343	$	24,189,438	$	24,173,406

Schedule of Unrealized Loss on Investments [Table Text Block]

	June 30, 2015					December 31, 2014
Description of Securities	Fair Value		Unrealized Holding Gains (Losses)			Fair Value		Unrealized Holding Gains (Losses)

Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains	$	6,080,493	$	2,329		–		–
Short-term investments with unrealized losses		12,697,850		(4,874	)		24,173,406		(16,032	)
Total	$	18,778,343	$	(2,545	)	$	24,173,406	$	(16,032	)

Investment Income [Table Text Block]

	Three Months Ended June 30,
Description of Securities	2015			2014

Interest and dividends accrued and paid	$	38,772		$	277,761
Accretion of investment premium		(21,569	)		(250,946	)
Realized losses		(339	)		(3,081	)
Investment income, net	$	16,865		$	23,734

	Six Months Ended June 30,
Description of Securities	2015			2014

Interest and dividends accrued and paid	$	131,974		$	580,975
Accretion of investment premium		(98,519	)		(526,531	)
Realized losses		(210	)		(23,691	)
Investment income, net	$	33,245		$	30,753

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

	Accumulated Other Comprehensive Loss
Balance at January 1, 2015	$	(16,032	)

Unrealized gains on investment securities		11,507
Realized loss reclassified from other accumulated comprehensive loss		210
Net other comprehensive loss, net		11,717

Balance at June 30, 2015	$	(4,315	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Note 6 - Fair Value of Measurements (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets / Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:
Recurring items as of June 30, 2015
Short-term investments available for sale	$	18,778,343	$	18,778,343	─	─

Recurring items as of December 31, 2014
Short-term investments available for sale	$	24,173,406	$	24,173,406	─	─

Non-recurring items as of December 31, 2014
In-process research and development (Note 7)	$	25,801,728	─		─	$	25,801,728

Goodwill (Note 7)	$	1,976,101	─		─	$	1,976,101

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets / Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Liabilities:
Recurring items as of June 30, 2015
Common stock warrant liability (Note 13)	─		─	─	─

Earn-out milestone liability (Note 12)	$	13,905,238	─	─	$	13,905,238

Recurring items as of December 31, 2014
Common stock warrant liability (Note 13)	$	275,008	─	─	$	275,008

Earn-out milestone liability (Note 12)	$	13,663,710	─	─	$	13,663,710

Note 7 - Acquisition of EGEN, Inc. (Tables)

6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Consideration Paid at Closing
Cash, net of cash acquired	$	2,821,000
Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)		9,438,000

Future Consideration
Holdback Shares (670,070 shares of Celsion common stock which were discounted by 38% to reflect the cost of the restriction)		1,441,000
Earn-out Payments (at fair value*)		13,878,000

Total fair value of consideration	$	27,578,000

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Property and equipment, net		35,000
In-process research and development		25,802,000
Goodwill		1,976,000
Total assets:		27,813,000
Accounts payable and accrued liabilities		(235,000	)
Net assets acquired	$	27,578,000

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended June 30,
	2015			2014
Revenues	$	125,000		$	125,000
Loss from operations		(5,244,542	)		(6,214,162	)
Net loss applicable to common shareholders		(5,674,745	)		(6,575,376	)

	Six Months Ended June 30,
	2015			2014
Revenues	$	250,000		$	250,000
Loss from operations		(11,657,790	)		(12,116,500	)
Net loss applicable to common shareholders		(12,679,813	)		(12,582,418	)

Note 8 - Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

	June 30, 2015		December 31, 2014
Amounts due to Contract Research Organizations and other contractual agreements	$	1,084,432	$	857,730
Accrued payroll and related benefits		612,920		961,440
Accrued professional fees		441,500		502,300
Accrued interest on notes payable		77,094		96,875
Other		20,020		38,020

Total Accrued Liabilities	$	2,235,966	$	2,456,365

Note 9 - Note Payable (Tables)

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

	For the Year ending June 30,

2016	$	3,865,219
2017		4,358,179

Total	$	8,223,398

Note 11 - Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Six Months Ended June 30,
	2015			2014
Risk-free interest rate		2.06-2.93	%		2.63 - 2.75	%
Expected volatility		92.9-93.0	%		98.7 - 100.72	%
Expected life (in years)		10.00			10.00
Expected forfeiture rate		5	%		5	%
Expected dividend yield		0.0	%		0.0	%

Schedule of Shar-based Compensation, Stock Options and Restricted Stock Awards, Activity [Table Text Block]

	Stock Options					Restricted Stock Awards					Weighted Average
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value		Contractual Terms of Equity Awards (in years)

Equity awards outstanding at December 31, 2014		1,744,755		$	7.20		7,018		$	3.32
Equity awards granted		709,250		$	2.44		36,000		$	3.47
Equity awards exercised	–			–			(1,500	)	$	2.54
Equity awards forfeited, cancelled or expired		(201,490	)	$	10.83	–			–
Equity awards outstanding at June 30, 2015		2,252,515		$	5.86		41,518		$	3.48		7.7

Aggregate intrinsic value of outstanding awards at June 30, 2015	–					$	110,853

Equity awards exercisable at June 30, 2015		1,421,390		$	7.56							6.8

Aggregate intrinsic value of awards exercisable June 30, 2015	–

Note 12 - Earn-out Milestone Liability (Tables)

6 Months Ended

Jun. 30, 2015

Earn Out Milestone Liability Disclosure [Abstract]

Schedule of Changes in Earn-Out Milestone Liabilites [Table Text Block]

Balance at January 1, 2015	$	13,663,710
Non-cash charge from the adjustment for the change in fair value included in net loss		241,528
Balance at June 30, 2015	$	13,905,238

Note 13 - Warrants (Tables)

6 Months Ended

Jun. 30, 2015

Warrants [Abstract]

Schedule of Warrant Activity [Table Text Block]

Warrants	Number of Warrants Issued			Weighted Average Exercise Price

Warrants outstanding at December 31, 2014		5,069,815		$	8.18

Warrants issued during the six months ended June 30, 2015		1,950,000		$	2.60

Warrants expired during the six months ended June 30, 2015		(1,125,140	)	$	7.98
Warrants outstanding at June 30, 2015		5,894,675		$	6.37

Aggregate intrinsic value of outstanding warrants at June 30, 2015	–

Weighted average remaining contractual terms (in years)		3.3

Schedule of Common Stock Warrant Liability Valuation Assumptions [Table Text Block]

	December 31, 2014
Risk-free interest rate		0.04 - 1.66	%
Expected volatility		40.9- 98.35	%
Expected life (in years)		0.25 -3.9
Expected forfeiture rate		0.0	%
Expected dividend yield		0.00	%

Schedule of Common Stock Warranty Liability [Table Text Block]

Beginning balance as of January 1, 2015	$	275,008
Loss from the adjustment for the change in fair value included in net loss		61,246
Fair value of warrants reclassified as equity (Note 9)		(336,254	)
Ending balance as of June 30, 2015	–

Note 4 - Net Loss per Common Share (Details) - shares	3 Months Ended		6 Months Ended
Note 4 - Net Loss per Common Share (Details) - shares	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	8,188,708	6,948,415	8,188,708	6,948,415

Note 5 - Investment Securities - Available for Sale (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Note 5 - Investment Securities - Available for Sale (Details) [Line Items]
Short-term Investments	$ 18,778,343	$ 24,173,406
Short Term Investments Available For Sale [Member]
Note 5 - Investment Securities - Available for Sale (Details) [Line Items]
Short-term Investments	$ 18,778,343	$ 24,173,406

Note 5 - Investment Securities - Available for Sale (Details) - Short-term Investment by Bond Maturities - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Short-term investments
Short-term investments, Cost	$ 18,780,888	$ 24,189,438
Short-term investments, Fair Value	18,778,343	24,173,406
Short-term investment maturities
Short-term investments maturities, Cost	18,780,888	24,189,438
Short-term investments maturities, Fair Value	18,778,343	24,173,406
Certificate of Deposit [Member]
Short-term investments
Short-term investments, Cost	4,760,000	5,000,000
Short-term investments, Fair Value	4,760,488	4,996,568
Corporate Debt Securities [Member]
Short-term investments
Short-term investments, Cost	14,020,888	19,189,438
Short-term investments, Fair Value	14,017,855	19,176,838
Investment Maturing Within 3 Months [Member]
Short-term investment maturities
Short-term investments maturities, Cost	7,601,405	16,881,490
Short-term investments maturities, Fair Value	7,601,830	16,872,158
Investment Maturing Between 3 and 12 Months [Member]
Short-term investment maturities
Short-term investments maturities, Cost	11,179,483	7,307,948
Short-term investments maturities, Fair Value	$ 11,176,513	$ 7,301,248

Note 5 - Investment Securities - Available for Sale (Details) - Investment Securities Gross Unrealized Losses and Fair Value by Investment Category - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Total	$ 18,778,343	$ 24,173,406
Total	(2,545)	(16,032)
Corporate Debt Securities [Member]
Available for Sale (all unrealized holding gains and losses are less than 12 months at date of measurement)
Short-term investments with unrealized gains	6,080,493
Short-term investments with unrealized gains	2,329
Short-term investments with unrealized losses	12,697,850	24,173,406
Short-term investments with unrealized losses	$ (4,874)	$ (16,032)

Note 5 - Investment Securities - Available for Sale (Details) - Investment Income - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Investment Income [Abstract]
Interest and dividends accrued and paid	$ 38,772	$ 277,761	$ 131,974	$ 580,975
Accretion of investment premium	(21,569)	(250,946)	(98,519)	(526,531)
Realized losses	(339)	(3,081)	(210)	(23,691)
Investment income, net	$ 16,865	$ 23,734	$ 33,245	$ 30,753

Note 5 - Investment Securities - Available for Sale (Details) - Component of Accumulated Other Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance at January 1, 2015			$ (16,032)
Realized loss reclassified from other accumulated comprehensive loss	$ 339	$ 3,081	210	$ 23,691
Net other comprehensive loss, net	3,639	$ 16,068	11,717	$ 32,337
Balance at June 30, 2015	$ (4,315)		(4,315)
Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrealized gains on investment securities			$ 11,507

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Note 6 - Fair Value of Measurements (Details) - Assets and Liabilities at Fair Value on a Recurring Basis - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Assets:
Short-term investments available for sale Bonds – corporate issuances	$ 18,778,343	$ 24,173,406
Non-recurring items as of December 31, 2014
Goodwill (Note 7)	1,976,101	1,976,101
Earn-out milestone liability (Note 11)	13,905,238	13,663,710
Fair Value, Measurements, Recurring [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances	18,778,343	24,173,406
Non-recurring items as of December 31, 2014
Earn-out milestone liability (Note 11)	13,905,238	13,663,710
Recurring items as of December 31, 2014
Common stock warrant liability (Note 13)		275,008
Fair Value, Measurements, Nonrecurring [Member]
Non-recurring items as of December 31, 2014
In-process research and development (Note 7)		25,801,728
Goodwill (Note 7)		1,976,101
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances	18,778,343	24,173,406
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member]
Assets:
Short-term investments available for sale Bonds – corporate issuances		0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Non-recurring items as of December 31, 2014
Earn-out milestone liability (Note 11)	$ 13,905,238	13,663,710
Recurring items as of December 31, 2014
Common stock warrant liability (Note 13)		275,008
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Nonrecurring [Member]
Non-recurring items as of December 31, 2014
In-process research and development (Note 7)		25,801,728
Goodwill (Note 7)		$ 1,976,101

Note 7 - Acquisition of EGEN, Inc. (Details) - EGEN, Inc. [Member] - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 10, 2014

Jun. 20, 2014

Mar. 31, 2015

Jun. 30, 2015

Dec. 31, 2014

Jun. 09, 2014

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Consideration Transferred

$ 27,600,000

$ 27,578,000

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 30,400,000

Payments to Acquire Businesses, Gross

$ 3,000,000

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in Shares)

2,712,188

670,070

Business Combination, Consideration Transferred, Liabilities Incurred

$ 13,900,000

$ 13,800,000

$ 13,878,000

^[1]

$ 13,700,000

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

13,900,000

Fair Value, Option, Changes in Fair Value, Gain (Loss)

241,528

Goodwill, Acquired During Period

2,000,000

Ovarian Cancer Study Milestone [Member]

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

12,400,000

Glioblastoma Multiforme Brain Cancer Study Milestone [Member]

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

12,000,000

TheraSilence Technology Milestone [Member]

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

6,000,000

Hercules Credit Agreement [Member]

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Payments to Acquire Businesses, Gross

$ 3,000,000

Loans Payable

$ 5,000,000

In Process Research and Development [Member]

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Finite-lived Intangible Assets Acquired

$ 25,800,000

Maximum [Member]

Note 7 - Acquisition of EGEN, Inc. (Details) [Line Items]

Business Combination, Consideration Transferred

$ 44,400,000

[1]

The total aggregate purchase price for the acquisition of substantially all the assets of EGEN included potential future Earn-out Payments contingent upon achievement of certain milestones. The difference between the aggregate $30.4 million in future Earn-out Payments and the $13.9 million included in the fair value of the acquisition consideration at June 20, 2014 was based on the Company's risk-adjusted assessment of each milestone and utilizing a discount rate based on the estimated time to achieve the milestone. These milestone payments will be fair valued at the end of each quarter and any change in their value will be recognized in the financial statements. As of June 30, 2015, the Company fair valued these milestones at $13.9 million and recognized a non-cash charge of $241,528 as a result of the change in the fair value of these milestones from December 31, 2014.

Note 7 - Acquisition of EGEN, Inc. (Details) - Fair Value of Consideration - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 20, 2014

Mar. 31, 2015

Jun. 30, 2015

Jun. 30, 2014

Dec. 31, 2014

Consideration Paid at Closing

Cash, net of cash acquired

$ 2,820,849

EGEN, Inc. [Member]

Consideration Paid at Closing

Cash, net of cash acquired

$ 2,821,000

Celsion common stock (2,712,188 shares valued at $3.48 which was the last closing price of our common stock at the time of closing the transaction on June 20, 2014)

9,438,000

Future Consideration

Holdback Shares (670,070 shares of Celsion common stock which were discounted by 38% to reflect the cost of the restriction)

$ 1,441,000

Earn-out Payments (at fair value*)

13,900,000

$ 13,800,000

13,878,000

^[1]

$ 13,700,000

Total fair value of consideration

$ 27,600,000

$ 27,578,000

[1]

Note 7 - Acquisition of EGEN, Inc. (Details) - Fair Value of Consideration (Parentheticals) - EGEN, Inc. [Member] - $ / shares	1 Months Ended	6 Months Ended
	Jun. 20, 2014	Jun. 30, 2015
Business Acquisition, Contingent Consideration [Line Items]
Common Stock, shares issued	2,712,188
Common Stock, price per share (in Dollars per share)	$ 3.48
Common Stock, shares to be issued	2,712,188	670,070
Common Stock, discount		38.00%

Note 7 - Acquisition of EGEN, Inc. (Details) - Summary of Estimated Fair Values of Acquired Assets and Liabilities - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Note 7 - Acquisition of EGEN, Inc. (Details) - Summary of Estimated Fair Values of Acquired Assets and Liabilities [Line Items]
Goodwill	$ 1,976,101	$ 1,976,101
EGEN, Inc. [Member]
Note 7 - Acquisition of EGEN, Inc. (Details) - Summary of Estimated Fair Values of Acquired Assets and Liabilities [Line Items]
Property and equipment, net		35,000
In-process research and development		25,802,000
Goodwill		1,976,000
Total assets:		27,813,000
Accounts payable and accrued liabilities		(235,000)
Net assets acquired		$ 27,578,000

Note 7 - Acquisition of EGEN, Inc. (Details) - Pro Forma Information - EGEN, Inc. [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Note 7 - Acquisition of EGEN, Inc. (Details) - Pro Forma Information [Line Items]
Revenues	$ 125,000	$ 125,000	$ 250,000	$ 250,000
Loss from operations	(5,244,542)	(6,214,162)	(11,657,790)	(12,116,500)
Net loss applicable to common shareholders	$ (5,674,745)	$ (6,575,376)	$ (12,679,813)	$ (12,582,418)

Note 8 - Accrued Liabilities (Details) - Accrued Liabilities - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Amounts due to Contract Research Organizations and other contractual agreements	$ 1,084,432	$ 857,730
Accrued payroll and related benefits	612,920	961,440
Accrued professional fees	441,500	502,300
Accrued interest on notes payable	77,094	96,875
Other	20,020	38,020
Total Accrued Liabilities	$ 2,235,966	$ 2,456,365

Note 9 - Note Payable (Details) - USD ($)		1 Months Ended				3 Months Ended			6 Months Ended
Note 9 - Note Payable (Details) - USD ($)	Jun. 10, 2014	Jun. 20, 2014	Nov. 30, 2013	Nov. 25, 2013	Jun. 30, 2012	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 10, 2014	Dec. 31, 2014	Jun. 09, 2014	Dec. 31, 2013
Note 9 - Note Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 6.37			$ 6.37			$ 8.18
Increase (Decrease) in Other Operating Assets									$ (241,528)
Gain (Loss) from Change in Valuation of Common Stock Warrant Liability						$ (18,018)		$ (18,613)	(61,246)	$ (15,587)
Common Stock Warrant Liability						0			0			$ 275,008
Classification of Warrants to (from) Common Stock Warrant Liability, Net						$ 336,254			(336,254)
EGEN, Inc. [Member]
Note 9 - Note Payable (Details) [Line Items]
Payments to Acquire Businesses, Gross		$ 3,000,000
Share Price (in Dollars per share)		$ 3.48
Oxford and Horizon [Member]
Note 9 - Note Payable (Details) [Line Items]
Repayments of Lines of Credit			$ 4,000,000
Hercules Warrant [Member]
Note 9 - Note Payable (Details) [Line Items]
Deferred Finance Costs, Net														$ 521,763
Fair Value Assumptions, Expected Volatility Rate	104.00%					99.71%
Fair Value Assumptions, Risk Free Interest Rate	1.69%					1.98%
Fair Value Assumptions, Expected Term	4 years 6 months					4 years
Share Price (in Dollars per share)	$ 3.07										$ 3.07
Increase (Decrease) in Other Operating Assets								(521,763)
Adjustments to Additional Paid in Capital, Other								(521,763)
Gain (Loss) from Change in Valuation of Common Stock Warrant Liability						$ (18,018)			(61,246)
Common Stock Warrant Liability						0			$ 0
Classification of Warrants to (from) Common Stock Warrant Liability, Net						$ (336,254)
Hercules Warrant [Member] \| First 50 Percent [Member]
Note 9 - Note Payable (Details) [Line Items]
Debt Instrument, Unamortized Discount								$ 260,928		$ 260,928
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)								97,493		97,493
Hercules Warrant [Member] \| Second 50 Percent [Member]
Note 9 - Note Payable (Details) [Line Items]
Debt Instrument, Unamortized Discount													$ 215,333
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)													97,493
Oxford & Horizon Warrants [Member]
Note 9 - Note Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 13.14			$ 13.14
Note Stock Conversion Rate									3.00%
Number of Warrants Issued (in Shares)							11,415
Warrants Issued, Expiration Period							7 years
Hercules Credit Agreement [Member]
Note 9 - Note Payable (Details) [Line Items]
Interest Expense, Debt						$ 242,421			$ 507,332
Amortization of Financing Costs						$ 117,838			$ 245,230
Hercules Credit Agreement [Member] \| EGEN, Inc. [Member]
Note 9 - Note Payable (Details) [Line Items]
Payments to Acquire Businesses, Gross	$ 3,000,000
Hercules Credit Agreement [Member] \| Hercules [Member]
Note 9 - Note Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			20,000,000
Proceeds from Lines of Credit	$ 5,000,000		$ 5,000,000								$ 10,000,000
Debt Instrument, Basis Spread on Variable Rate			11.25%
Deferred Finance Costs, Net			$ 122,378
Debt Instrument, Unamortized Discount			$ 230,000
Line of Credit Facility, Original Loan Fee, Percent						3.50%			3.50%
Deferred Finance Costs, Gross						$ 350,000			$ 350,000
Hercules Credit Agreement [Member] \| Hercules Warrant [Member]
Note 9 - Note Payable (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 3.59
Fair Value Assumptions, Expected Volatility Rate				102.00%
Fair Value Assumptions, Risk Free Interest Rate				1.37%
Fair Value Assumptions, Expected Term				5 years
Share Price (in Dollars per share)				$ 3.55
Hercules Credit Agreement [Member] \| Hercules Warrant [Member] \| First 50 Percent [Member]
Note 9 - Note Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)				97,493
Hercules Credit Agreement [Member] \| Hercules Warrant [Member] \| Second 50 Percent [Member]
Note 9 - Note Payable (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in Shares)	97,493										97,493
Oxford and Horizon Credit Agreement [Member]
Note 9 - Note Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity					$ 10,000,000
Loan Tranche Amount					$ 5,000,000
Repayments of Secured Debt									$ 4,100,000
Oxford and Horizon Credit Agreement [Member] \| Oxford [Member]
Note 9 - Note Payable (Details) [Line Items]
Debt Instrument, Percentage Funded by Certain Lender					50.00%
Oxford and Horizon Credit Agreement [Member] \| Horizon [Member]
Note 9 - Note Payable (Details) [Line Items]
Debt Instrument, Percentage Funded by Certain Lender					50.00%

Note 9 - Note Payable (Details) - Future Principal Payments Due on the Credit Agreement - Hercules Credit Agreement [Member]	Jun. 30, 2015 USD ($)
Note 9 - Note Payable (Details) - Future Principal Payments Due on the Credit Agreement [Line Items]
2016	$ 3,865,219
2017	4,358,179
Total	$ 8,223,398

Note 10 - Stockholders' Equity (Details) - USD ($)							1 Months Ended	6 Months Ended		12 Months Ended
Note 10 - Stockholders' Equity (Details) - USD ($)	May 27, 2015	Jan. 15, 2014	Oct. 28, 2013	Feb. 26, 2013	Feb. 22, 2013	Feb. 02, 2013	Feb. 25, 2013	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2015	Feb. 21, 2013
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 6.37		$ 8.18
Proceeds from Issuance of Common Stock (in Dollars)								$ 7,249,750	$ 13,788,811
Conversion of Stock, Shares Issued			2
Conversion of Stock, Shares Converted			9
May 2015 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	3,000,000
Share Price (in Dollars per share)	$ 2.675
Proceeds from Issuance of Common Stock, Gross (in Dollars)	$ 8,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 2.60
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.65
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,950,000
Warrants Issued, Expiration Period	5 years
Common Stock Offering, Period of Restriction, Common Stock	3 months
Common Stock Offering, Period of Restriction	5 months
January 2014 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		3,603,604
Share Price (in Dollars per share)		$ 4.1625
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 4.10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,801,802
Stock Issued During Period, Value, New Issues (in Dollars)		$ 15,000,000
Common Stock, Shares Per Unit		1
ATM Agreement [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues							1,195,927
Aggregate Offering Price (in Dollars)						$ 25,000,000
Proceeds from Issuance of Common Stock (in Dollars)							$ 6,800,000
Commission on Proceeds from ATM Shares, Percent										3.00%
Legal Fees (in Dollars)										$ 50,000
February 2013 Preferred Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)													$ 5.31
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,341,382
Warrants Issued, Expiration Period				5 years
Proceeds from Issuance or Sale of Equity (in Dollars)				$ 15,000,000
Conversion of Stock, Shares Issued											2,682,764
Series A Convertible Preferred Stock (Member) \| February 2013 Preferred Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					15,000.00422
Convertible Preferred Stock, Shares Issued upon Conversion				2,682,764
Conversion of Stock, Shares Converted											15,000.00422
Series A Warrant [Member] \| January 2014 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.25
Warrants Issued, Expiration Period		5 years
Series B Warrant [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights												900,901
Series B Warrant [Member] \| January 2014 Common Stock Offering [Member]
Note 10 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		0.25

Note 11 - Stock Based Compensation (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
Note 11 - Stock Based Compensation (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2007	Dec. 31, 2006
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	3,672,770		3,672,770
Stock Issued During Period, Shares, Share-based Compensation, Gross			2,294,033
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,378,737		1,378,737
Stock Incentive Plan 2007 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized					3,444,444	944,444	444,444	222,222
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					2,500,000	500,000	222,222
Allocated Share-based Compensation Expense (in Dollars)	$ 462,468	$ 1,035,196	$ 1,310,081	$ 1,721,476
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount (in Dollars)			0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	$ 1,300,000		$ 1,300,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 109 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)			$ 2.15	$ 3.19
Stock Incentive Plan 2001 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									148,148
Stock Incentive Plan 2004 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									148,148
Employee Stock Option [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Restricted Stock [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)			$ 3.47
Restricted Stock [Member] \| Stock Incentive Plan 2007 [Member]
Note 11 - Stock Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)			$ 3.47	$ 3.72

Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions [Line Items]
Expected life (in years)	10 years	10 years
Expected forfeiture rate	5.00%	5.00%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions [Line Items]
Risk-free interest rate	2.06%	2.63%
Expected volatility	92.90%	98.70%
Maximum [Member]
Note 11 - Stock Based Compensation (Details) - Fair Value of Option Assumptions [Line Items]
Risk-free interest rate	2.93%	2.75%
Expected volatility	93.00%	100.72%

Note 11 - Stock Based Compensation (Details) - Stock Option and Restricted Stock Awards - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Note 11 - Stock Based Compensation (Details) - Stock Option and Restricted Stock Awards [Line Items]
Stock Options Outstanding		1,744,755
Stock Options, Weighted Average Exercise Price		$ 7.20
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 255 days
Equity awards exercisable at June 30, 2015	1,421,390
Equity awards exercisable at June 30, 2015	$ 7.56
Equity awards exercisable at June 30, 2015	6 years 292 days
Equity awards granted	709,250
Equity awards granted	$ 2.44
Equity awards forfeited, cancelled or expired	(201,490)
Equity awards forfeited, cancelled or expired	$ 10.83
Stock Options Outstanding	2,252,515
Stock Options, Weighted Average Exercise Price	$ 5.86
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	7 years 255 days
Restricted Stock [Member]
Note 11 - Stock Based Compensation (Details) - Stock Option and Restricted Stock Awards [Line Items]
Restricted Stock, Nonvested Stock Outstanding		7,018
Restricted Stock, Weighted Average Grant Date Fair Value		$ 3.32
Aggregate intrinsic value of outstanding awards at June 30, 2015	$ 110,853
Equity awards granted	36,000
Equity awards granted	$ 3.47
Equity awards exercised	(1,500)
Equity awards exercised	$ 2.54
Restricted Stock, Nonvested Stock Outstanding	41,518
Restricted Stock, Weighted Average Grant Date Fair Value	$ 3.48

Note 12 - Earn-out Milestone Liability (Details) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Dec. 31, 2014

Jun. 20, 2014

Jun. 30, 2015

Mar. 31, 2015

Jun. 30, 2015

Dec. 31, 2014

Note 12 - Earn-out Milestone Liability (Details) [Line Items]

Gain (Loss) From Change in Fair Value of Earn-Out Milestone Liability

$ 241,528

EGEN, Inc. [Member]

Note 12 - Earn-out Milestone Liability (Details) [Line Items]

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$ 30,400,000

30,400,000

$ 30,400,000

Business Combination, Consideration Transferred, Liabilities Incurred

$ 13,900,000

$ 13,800,000

13,878,000

^[1]

$ 13,700,000

Gain (Loss) From Change in Fair Value of Earn-Out Milestone Liability

$ 69,392

$ 241,528

Minimum [Member] | EGEN, Inc. [Member]

Note 12 - Earn-out Milestone Liability (Details) [Line Items]

Risk-Adjusted Assessment of Each Milestone

10.00%

Estimated Time to Achieve the Milestone

1 year 73 days

1 year 6 months

328 days

Maximum [Member] | EGEN, Inc. [Member]

Note 12 - Earn-out Milestone Liability (Details) [Line Items]

Risk-Adjusted Assessment of Each Milestone

67.00%

Estimated Time to Achieve the Milestone

6 years 6 months

7 years

3 years

[1]

Note 12 - Earn-out Milestone Liability (Details) - Summary of the Changes in the Earn-out Milestone Liability	6 Months Ended
	Jun. 30, 2015 USD ($)
Summary of the Changes in the Earn-out Milestone Liability [Abstract]
Balance	$ 13,663,710
Non-cash charge from the adjustment for the change in fair value included in net loss	241,528
Balance	$ 13,905,238

Note 13 - Warrants (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
Note 13 - Warrants (Details) - USD ($)	Jun. 10, 2014	Sep. 30, 2009	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jan. 31, 2015	Dec. 31, 2014
Note 13 - Warrants (Details) [Line Items]
Common Stock Warrant Liability			$ 0		$ 0			$ 275,008
Gain (Loss) from Change in Valuation of Common Stock Warrant Liability			(18,018)	$ (18,613)	(61,246)	$ (15,587)
Classification of Warrants to (from) Common Stock Warrant Liability, Net			336,254		(336,254)
September 2009 Registered Direct Offering [Member]
Note 13 - Warrants (Details) [Line Items]
Proceeds from Issuance or Sale of Equity		$ 7,100,000
Proceeds from Issuance or Sale of Equity, Net		$ 6,300,000
Common Stock and Warrants Issued, Shares (in Shares)		448,478
September 2009 Warrants [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		224,239
Series B Warrant [Member]
Note 13 - Warrants (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)							900,901
Hercules Warrant [Member]
Note 13 - Warrants (Details) [Line Items]
Common Stock Warrant Liability			$ 0		0
Fair Value Assumptions, Risk Free Interest Rate	1.69%		1.98%
Fair Value Assumptions, Expected Volatility Rate	104.00%		99.71%
Fair Value Assumptions, Expected Term	4 years 6 months		4 years
Fair Value Assumptions, Expected Dividend Rate			0.00%
Gain (Loss) from Change in Valuation of Common Stock Warrant Liability			$ (18,018)		$ (61,246)
Classification of Warrants to (from) Common Stock Warrant Liability, Net			$ (336,254)

Note 13 - Warrants (Details) - Summary of Warrant Activity	6 Months Ended
	Jun. 30, 2015 $ / shares shares
Summary of Warrant Activity [Abstract]
Number of Warrants Issued \| shares	5,894,675
Weighted Average Exercise Price \| $ / shares	$ 6.37
Weighted average remaining contractual terms (in years)	3 years 109 days
Warrants issued during the six months ended June 30, 2015 \| shares	1,950,000
Warrants issued during the six months ended June 30, 2015 \| $ / shares	$ 2.60
Warrants expired during the six months ended June 30, 2015 \| shares	(1,125,140)
Warrants expired during the six months ended June 30, 2015 \| $ / shares	$ 7.98

Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions - Warrant [Member]	12 Months Ended
	Dec. 31, 2014
Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions [Line Items]
Expected forfeiture rate	0.00%
Expected dividend yield	0.00%
Minimum [Member]
Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions [Line Items]
Risk-free interest rate	0.04%
Expected volatility	40.90%
Expected life (in years)	3 months
Maximum [Member]
Note 13 - Warrants (Details) - Fair Value of Warrants Assumptions [Line Items]
Risk-free interest rate	1.66%
Expected volatility	98.35%
Expected life (in years)	3 years 328 days

Note 13 - Warrants (Details) - Common Stock Warrant Liability - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Common Stock Warrant Liability [Abstract]
Common Stock Warrant Liability		$ 275,008
Loss from the adjustment for the change in fair value included in net loss		61,246
Fair value of warrants reclassified as equity (Note 9)	$ 336,254	(336,254)
Common Stock Warrant Liability	$ 0	$ 0

Note 14 - Contingent Liabilities and Commitments (Details)	1 Months Ended
	Jun. 30, 2014 USD ($) ft²	Apr. 30, 2014 USD ($)	Apr. 30, 2013 USD ($)	Apr. 30, 2012 USD ($)	Jul. 31, 2011 ft²	Jun. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)
Note 14 - Contingent Liabilities and Commitments (Details) [Line Items]
Contractual Obligation						$ 1,084,432	$ 857,730
Reduction of Escrow Deposit		$ 50,000	$ 50,000
Standby Letters of Credit [Member]
Note 14 - Contingent Liabilities and Commitments (Details) [Line Items]
Contractual Obligation Reduction Forty-Three Months from Initial Term				$ 50,000
Contractual Obligation Reduction Nineteen Months from Initial Term				50,000
Contractual Obligation Reduction Thirty-One Months from Initial Term				50,000
Contractual Obligation Remaining				100,000
Lawrenceville, New Jersey [Member]
Note 14 - Contingent Liabilities and Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²					10,870
Lessee Leasing Arrangements, Operating Leases, Term of Contract					66 months
Number of Months in Which Free Rent is Provided					6 months
Payments for Rent				23,000
Escrow Deposit Related To Operating Lease				250,000
Lawrenceville, New Jersey [Member] \| Standby Letters of Credit [Member]
Note 14 - Contingent Liabilities and Commitments (Details) [Line Items]
Contractual Obligation				$ 250,000
Premises Located in Huntsville, Alabama [Member]
Note 14 - Contingent Liabilities and Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet) \| ft²	11,500
Lessee Leasing Arrangements, Operating Leases, Term of Contract	32 months
Operating Leases, Monthly Rent Payment	$ 23,200

Note 15 - Technology Development and Licensing Agreements (Details) - USD ($)		1 Months Ended	3 Months Ended
	Jan. 18, 2013	Jan. 31, 2011	Mar. 31, 2013	Dec. 31, 2008	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014
Note 15 - Technology Development and Licensing Agreements (Details) [Line Items]
Contractual Obligation					$ 1,084,432		$ 857,730
Deferred Revenue			$ 5,000,000
Deferred Revenue Amortization Period			10 years
Hisun [Member]
Note 15 - Technology Development and Licensing Agreements (Details) [Line Items]
Contractual Obligation						$ 685,787
Proceeds from License Fees Received	$ 5,000,000
Yakult [Member]
Note 15 - Technology Development and Licensing Agreements (Details) [Line Items]
Proceeds from License Fees Received				$ 2,500,000
Percentage Reduction On Milestone Payments		40.00%
Yakult [Member] \| Drug Approval Milestone [Member]
Note 15 - Technology Development and Licensing Agreements (Details) [Line Items]
Contract Receivable		$ 4,000,000
Yakult [Member] \| Patients Enrollment in Heat Study [Member]
Note 15 - Technology Development and Licensing Agreements (Details) [Line Items]
Contract Receivable		2,000,000
Yakult [Member] \| Preferred Equity Financing [Member]
Note 15 - Technology Development and Licensing Agreements (Details) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock		$ 2,000,000

Label	Element	Value
Class of Warrant or Right, Outstanding	us-gaap_ClassOfWarrantOrRightOutstanding	5,069,815